Optimizing Vessel Preparation in Femoropopliteal Lesions: Does the Chocolate Balloon Deliver on Its Clinical Promise?

The "leave nothing behind" paradigm using drug-coated balloons (DCBs) has reshaped femoropopliteal peripheral artery disease treatment, though clinical success remains heavily contingent upon optimal vessel preparation. In a recent issue of The American Journal of Cardiology, Li and colleagues address the limitations of conventional plain old balloon angioplasty (POBA) through a propensity score-matched analysis of 508 patients from the multicenter PROMISING registry, comparing specialized vessel preparation using the nitinol-constrained Chocolate balloon against POBA prior to DCB angioplasty. The Chocolate balloon significantly reduced the primary endpoint of bailout stenting (20.47% vs. 29.92%) and facilitated larger final DCB diameters, though these acute mechanical advantages did not translate into statistically significant differences in clinical outcomes at 12 months. This commentary examines this striking "procedural-to-clinical paradox," highlighting how the potent antiproliferative effect of DCBs and the acute compensatory function of bailout stents may temporarily mask early clinical divergence. Given that cumulative mechanical failures of permanent metallic implants typically emerge beyond one year in hostile biomechanical environments, longer-term observation remains essential to capture the true clinical dividend of a stent-free strategy.